Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Accupril patent litigation

Executive Summary

Trial in Pfizer's infringement case against Teva relating to the blood pressure agent Accupril (quinapril) will be limited to the validity of Pfizer's formulation patent claims and whether Warner-Lambert engaged in inequitable conduct in obtaining the patent. On Oct. 2, the court granted Pfizer's motion for summary judgment on infringement but rejected the company's motion for summary judgment on the validity of two patent claims...
Advertisement

Related Content

Mutual’s Accupril Declaratory Judgment Case Versus Pfizer Thrown Out
Pfizer Accupril Patent Invalid Due To Inequitable Conduct, Lawsuit Alleges
Advertisement
UsernamePublicRestriction

Register

PS042592

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel